6744 Stock Overview
Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Feng Chi Biotech Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$22.45 |
52 Week High | NT$32.75 |
52 Week Low | NT$21.15 |
Beta | 0.046 |
1 Month Change | -1.97% |
3 Month Change | -3.44% |
1 Year Change | -8.37% |
3 Year Change | -26.39% |
5 Year Change | n/a |
Change since IPO | -53.42% |
Recent News & Updates
Shareholder Returns
6744 | TW Healthcare | TW Market | |
---|---|---|---|
7D | 1.8% | -0.6% | 1.1% |
1Y | -8.4% | -3.2% | 26.7% |
Return vs Industry: 6744 underperformed the TW Healthcare industry which returned -3.2% over the past year.
Return vs Market: 6744 underperformed the TW Market which returned 26.7% over the past year.
Price Volatility
6744 volatility | |
---|---|
6744 Average Weekly Movement | 3.3% |
Healthcare Industry Average Movement | 3.9% |
Market Average Movement | 4.2% |
10% most volatile stocks in TW Market | 7.9% |
10% least volatile stocks in TW Market | 1.9% |
Stable Share Price: 6744 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6744's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | n/a | https://www.fcbiotech.com.tw |
Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various genetic testing technologies and products in oncology. The company is based in Taipei, Taiwan.
Feng Chi Biotech Corp. Fundamentals Summary
6744 fundamental statistics | |
---|---|
Market cap | NT$345.73m |
Earnings (TTM) | NT$24.11m |
Revenue (TTM) | NT$183.66m |
14.3x
P/E Ratio1.9x
P/S RatioIs 6744 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6744 income statement (TTM) | |
---|---|
Revenue | NT$183.66m |
Cost of Revenue | NT$101.60m |
Gross Profit | NT$82.05m |
Other Expenses | NT$57.94m |
Earnings | NT$24.11m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 1.57 |
Gross Margin | 44.68% |
Net Profit Margin | 13.13% |
Debt/Equity Ratio | 0% |
How did 6744 perform over the long term?
See historical performance and comparison